HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hicke, B. J. Articles by Schmidt, P. G. Search for Related Content PubMed PubMed Citation Articles by Hicke, B. J. Articles by Schmidt, P. G.

Tumor Targeting by an Aptamer

¹ NeXstar Pharmaceuticals, Boulder, Colorado; and ² Schering AG, Berlin, Germany

Correspondence: For correspondence or reprints contact: Brian J. Hicke, Global Technologies (NZ) Ltd., 218 George St., P.O. Box 941, Dunedin 9001, New Zealand. E-mail: bhicke{at}gmail.com

Aptamers are small oligonucleotides that are selected to bind tightly and specifically to a target molecule. We sought to determine whether aptamers have potential for in vivo delivery of radioisotopes or cytotoxic agents. Methods: TTA1, an aptamer to the extracellular matrix protein tenascin-C, was prepared in fluorescent and radiolabeled forms. After in vivo administration, uptake and tumor distribution of Rhodamine Red-X–labeled aptamer was studied by fluorescence microscopy. In glioblastoma (U251) and breast cancer (MDA-MB-435) tumor xenografts, biodistribution and imaging studies were performed using TTA1 radiolabeled with ^99mTc. Tenascin-C levels and tumor uptake were studied in a variety of additional human tumor xenografts. To assess the effect of radiometal chelate on biodistribution, mercapto-acetyl diglycine (MAG₂) was compared with diethylenetriaminepentaacetic acid and with MAG₂–3,400-molecular-weight PEG (PEG_3,400). Results: Intravenous injection of fluorescent aptamer TTA1 produced bright perivascular fluorescence in a xenografted human tumor within 10 min. In the ensuing 3 h, fluorescence diffused throughout the tumor. Labeled with ^99mTc, TTA1 displayed rapid blood clearance, a half-life of less than 2 min, and rapid tumor penetration: 6% injected dose (%ID)/g at 10 min. Tumor retention was durable, with 2.7 %ID/g at 60 min and a long-lived phase that stabilized at 1 %ID/g. Rapid tumor uptake and blood clearance yielded a tumor-to-blood ratio of 50 within 3 h. Both renal and hepatic clearance pathways were observed. Using the ^99mTc-labeled aptamer, images of glioblastoma and breast tumors were obtained by planar scintigraphy. Aptamer uptake, seen in several different human tumors, required the presence of the target protein, human tenascin-C. Modification of the MAG₂ radiometal chelator dramatically altered the uptake and clearance patterns. Conclusion: TTA1 is taken up by a variety of solid tumors including breast, glioblastoma, lung, and colon. Rapid uptake by tumors and rapid clearance from the blood and other nontarget tissues enables clear tumor imaging. As synthetic molecules, aptamers are readily modified in a site-specific manner. A variety of aptamer conjugates accumulate in tumors, suggesting imaging and potentially therapeutic applications.

Key Words: SELEX • imaging • extracellular matrix • tenascin-C • oligonucleotide

Related articles in JNM:

This Month in JNM

JNM 2006 47: 9a-10a. [Full Text]  

This article has been cited by other articles:

				A. Taraseviciute, B. T. Vincent, P. Schedin, and P. L. Jones Quantitative Analysis of Three-Dimensional Human Mammary Epithelial Tissue Architecture Reveals a Role for Tenascin-C in Regulating c-Met Function Am. J. Pathol., February 1, 2010; 176(2): 827 - 838. [Abstract] [Full Text] [PDF]

				D. W. Hwang, H. Y. Ko, J. H. Lee, H. Kang, S. H. Ryu, I. C. Song, D. S. Lee, and S. Kim A Nucleolin-Targeted Multimodal Nanoparticle Imaging Probe for Tracking Cancer Cells Using an Aptamer J. Nucl. Med., January 1, 2010; 51(1): 98 - 105. [Abstract] [Full Text] [PDF]

				S. Javaherian, M. U. Musheev, M. Kanoatov, M. V. Berezovski, and S. N. Krylov Selection of aptamers for a protein target in cell lysate and their application to protein purification Nucleic Acids Res., May 1, 2009; 37(8): e62 - e62. [Abstract] [Full Text] [PDF]

				P. T. Winnard Jr., A. P. Pathak, S. Dhara, S. Y. Cho, V. Raman, and M. G. Pomper Molecular Imaging of Metastatic Potential J. Nucl. Med., June 1, 2008; 49(Suppl_2): 96S - 112S. [Abstract] [Full Text] [PDF]

				K. Cho, X. Wang, S. Nie, Z. Chen, and D. M. Shin Therapeutic Nanoparticles for Drug Delivery in Cancer Clin. Cancer Res., March 1, 2008; 14(5): 1310 - 1316. [Abstract] [Full Text] [PDF]

				A. D. Ellington, J. Ebright, T. Chu, and M. Levy Using Aptamers for Cell-Specific Labeling and Delivery Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 51 - 55. [Full Text] [PDF]

				S. R. Blumen, K. Cheng, M. E. Ramos-Nino, D. J. Taatjes, D. J. Weiss, C. C. Landry, and B. T. Mossman Unique Uptake of Acid-Prepared Mesoporous Spheres by Lung Epithelial and Mesothelioma Cells Am. J. Respir. Cell Mol. Biol., March 1, 2007; 36(3): 333 - 342. [Abstract] [Full Text] [PDF]